Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Bortezomib is a proteasome inhibitor with remarkable preclinical and clinical antitumor activity in multiple myeloma (MM) patients. The initial rationale for its use in MM was inhibition of nuclear factor (NF)-κB activity by blocking proteasomal degradation of inhibitor of κBα (IκBα). Bortezomib inh...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hideshima, Teru, Ikeda, Hiroshi, Chauhan, Dharminder, Okawa, Yutaka, Raje, Noopur, Podar, Klaus, Mitsiades, Constantine, Munshi, Nikhil C., Richardson, Paul G., Carrasco, Ruben D., Anderson, Kenneth C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2009
Teme:
Lymphoid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721785/
https://ncbi.nlm.nih.gov/pubmed/19436050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-01-199604
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items